养血清脑颗粒治疗卒中后轻中度抑郁的临床疗效观察

发布时间：2018-03-02 04:14

本文关键词： 卒中后抑郁养血清脑颗粒蒙哥马利-艾森贝格抑郁量表汉密尔顿抑郁量表　出处：《南京中医药大学》2017年硕士论文　论文类型：学位论文

【摘要】：研究目的:探索养血清脑颗粒治疗卒中后轻中度抑郁的临床疗效及安全性,为未来研究提供参考。研究方法:采用多中心、自身前后对照的研究方法,对符合卒中后抑郁诊断标准(轻中度)的神经内科门诊/住院病人,在脑梗死及基础病治疗基础上给予养血清脑颗粒口服(4g/次,3次/日,共12周)。分别在治疗前(第0日)、治疗2周、6周、12周后评定其MADRS评分、HAMD17评分及HAMA评分,并分别在治疗前及治疗12周后评定其NIHSS评分,记录服药期间不良反应。采用SPSS 21.0统计软件进行数据资料分析,比较治疗前后各量表评分变化,以及不良反应发生情况。结果:本研究共纳入患者32例,完成研究31例,其中男性21例,女性10例,平均年龄66.19±7.95岁,平均病程4.28±2.62周;失访1例。养血清脑颗粒治疗2周、6周、12周后MADRS 评分分别为 14.936±4.195、12.097±2.737、8.936±1.263,HAMD17 评分分别为13.839±3.226、11.548±2.307、7.968±1.303,HAMA 评分分别为 8.258±2.113、7.548±2.111、6.452±2.047。以上指标均较第0日有明显不同,差异具有统计学意义(P0.05);治疗12周后基于MADRS评分及HAMD17评分减分率判定的有效率分别为70.97%、67.74%。治疗12周后NIHSS评分与第0日比较有改善且差异具有统计学意义(P0.05)。完成试验的31例病人均无不良反应出现。结论:初步表明养血清脑颗粒治疗卒中后轻中度抑郁有效,且安全性良好。本研究的样本含量及研究方法使结论具有局限性,需大样本、设计更为严谨的试验进一步验证。
[Abstract]:Objective: to explore the clinical efficacy and safety of Yangxuannao granule in the treatment of mild to moderate depression after stroke, and to provide a reference for future research. The outpatients / inpatients of neurology who met the diagnostic criteria of post-stroke depression (mild to moderate) were given Yangxuanao granule 3 times a day on the basis of the treatment of cerebral infarction and basic diseases. The MADRS score, HAMD17 score and HAMA score were evaluated before and after treatment (day 0, 2 weeks and 6 weeks and 12 weeks later, respectively), and their NIHSS scores were evaluated before and after 12 weeks of treatment. Adverse reactions during medication were recorded. Data were analyzed by SPSS 21. 0 statistical software. The scores of each scale before and after treatment were compared. Results: 32 patients were included in this study, and 31 patients completed the study. There were 21 males and 10 females with an average age of 66.19 卤7.95 years and an average course of 4.28 卤2.62 weeks. The MADRS scores were 14.936 卤4.195 卤12.097 卤2.737 卤8.936 卤1.263 HMD17, 13.839 卤3.2266.548 卤2.307 卤7.968 卤1.303 Hama, 8.258 卤2.113 卤7.548 卤2.111 卤6.452 卤47.7, respectively. After 12 weeks of treatment, the effective rate based on MADRS score and HAMD17 score reduction rate were 70.97 and 67.745.After 12 weeks of treatment, the NIHSS score was improved compared with that on day 0, and the difference was statistically significant (P 0.05). Conclusion: Yangxuannao granule is effective in treating mild and moderate depression after stroke. The safety is good. The conclusion of this study is limited by sample content and research method, and needs to be further verified by a more rigorous design test.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R743.3

【参考文献】